Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Recruiting

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates

Outcome
Ongoing
Phase
No phase (not a drug trial)
Status
Recruiting
Study type
Interventional
Start
8 September 2023
Expected end
September 2027
Enrollment
20 participants
Sites
7
Primary outcomes
Change of MPMspecific VOCs
Sponsor type
Academic / other
Results posted
No
Last update
24 September 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.